Wire · opportunities
Ultragenyx gets FDA nod for first Sanfilippo A gene therapy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
Ultragenyx received FDA approval for the first gene therapy targeting Sanfilippo syndrome type A, marking a significant regulatory milestone for rare genetic disease treatments in the United States.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 17 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
FDA approval for Ultragenyx' gene therapy clears a direct path for rare disease startups to advance treatments without long regulatory delays. You must accelerate access strategies and partnerships now to capitalise on this cleared regulatory route.
◆ Coverage
9 sources · first reported 17 Sep 2026 · latest 28 Sep 2026
◆ Topics